1. Home
  2. SILC vs ADAG Comparison

SILC vs ADAG Comparison

Compare SILC & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicom Ltd

SILC

Silicom Ltd

HOLD

Current Price

$48.58

Market Cap

267.6M

Sector

Technology

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$2.97

Market Cap

222.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SILC
ADAG
Founded
1987
2011
Country
Israel
China
Employees
N/A
128
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.6M
222.2M
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
SILC
ADAG
Price
$48.58
$2.97
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
164.7K
190.3K
Earning Date
04-30-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.17
N/A
Revenue Next Year
$12.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.34
$1.44
52 Week High
$52.95
$4.85

Technical Indicators

Market Signals
Indicator
SILC
ADAG
Relative Strength Index (RSI) 60.80 N/A
Support Level $38.57 N/A
Resistance Level $52.52 N/A
Average True Range (ATR) 2.56 0.00
MACD 0.88 0.00
Stochastic Oscillator 86.45 0.00

Price Performance

Historical Comparison
SILC
ADAG

About SILC Silicom Ltd

Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: